Felipe D�ez-Delhoyo, Pablo D�ez-Villanueva, Mar�a Thiscal L�pez Lluva, Mar�a Abellas, Ignacio Amat-Santos, Pablo Bazal-Chac�n, Anna Carrasquer, Miguel Corb�, David Escribano, Ane Elorriaga, Sergio Garc�a-Blas, Teresa Giralt-Borrell, Alfonso Jurado-Rom�n, Isaac Lla�, Luc�a Matute-Blanco, Mart�n Negreira-Caama�o, Luc�a P�rez-Cebey, Ricardo Rivera-L�pez, Carolina Robles-Gamboa, Pablo Salinas, Fernando Jos� Torres Mezc�a, Iv�n Olavarri-Miguel, Jessica Vaquero-Luna, and, and Pedro Cepas-Guill�n
Introduction and objectives: The optimal time to perform a diagnostic coronary angiography in patients admitted due to non- ST-segment elevation acute coronary syndrome (NSTEACS) and start pretreatment with dual antiplatelet therapy is controversial. Our study aims to identify the current diagnostic and therapeutic approach, and clinical progression of patients with NSTEACS in our country. Methods: The IMPACT-TIMING-GO trial (Impact of time of intervention in patients with myocardial infarction with non-ST segment elevation. Management and outcomes) is a national, observational, prospective, and multicenter registry that will include consecutive patients from 24 Spanish centers with a clinical diagnosis of NSTEACS treated with diagnostic coronary angiography and with present unstable or causal atherosclerotic coronary artery disease. The study primary endpoint is to assess the level of compliance to clinical practice guidelines in patients admitted due to NSTEACS undergoing coronary angiography in Spain, describe the use of antithrombotic treatment prior to cardiac catheterization, and register the time elapsed until it is performed. Major adverse cardiovascular events will also be described like all-cause mortality, non-fatal myocardial infarction and non-fatal stroke, and the rate of major bleeding according to the BARC (Bleeding Academic Research Consortium) scale at 1- and 3-year follow-up. Results: This study will provide more information on the impact of different early management strategies in patients admitted with NSTEACS in Spain, and the degree of implementation of current recommendations into the routine clinical practice. It will also provide information on these patients' baseline and clinical characteristics. Conclusions: This is the first prospective study conducted in Spain that will be reporting on the early therapeutic strategies-both pharmacological and interventional-implemented in our country in patients with NSTEACS after the publication of the 2020 European guidelines, and on the clinical short- and long-term outcomes of these patients.